China Resources Pharmaceutical Group Balance Sheet Health
Financial Health criteria checks 5/6
China Resources Pharmaceutical Group has a total shareholder equity of CN¥93.0B and total debt of CN¥60.9B, which brings its debt-to-equity ratio to 65.5%. Its total assets and total liabilities are CN¥246.8B and CN¥153.8B respectively. China Resources Pharmaceutical Group's EBIT is CN¥11.0B making its interest coverage ratio 6.2. It has cash and short-term investments of CN¥24.7B.
Key information
65.5%
Debt to equity ratio
CN¥60.85b
Debt
| Interest coverage ratio | 6.2x |
| Cash | CN¥24.65b |
| Equity | CN¥92.97b |
| Total liabilities | CN¥153.80b |
| Total assets | CN¥246.77b |
Recent financial health updates
We Think China Resources Pharmaceutical Group (HKG:3320) Is Taking Some Risk With Its Debt
Dec 06
Does China Resources Pharmaceutical Group (HKG:3320) Have A Healthy Balance Sheet?
Sep 07These 4 Measures Indicate That China Resources Pharmaceutical Group (HKG:3320) Is Using Debt Reasonably Well
May 05Is China Resources Pharmaceutical Group (HKG:3320) Using Too Much Debt?
Dec 15China Resources Pharmaceutical Group (HKG:3320) Takes On Some Risk With Its Use Of Debt
Aug 27China Resources Pharmaceutical Group (HKG:3320) Has A Somewhat Strained Balance Sheet
Mar 31Recent updates
China Resources Pharmaceutical Group (HKG:3320) Is Increasing Its Dividend To CN¥0.1697
Apr 14China Resources Pharmaceutical Group's (HKG:3320) Dividend Will Be Increased To CN¥0.1697
Mar 28China Resources Pharmaceutical Group Limited's (HKG:3320) Shares May Have Run Too Fast Too Soon
Jan 28We Think China Resources Pharmaceutical Group (HKG:3320) Is Taking Some Risk With Its Debt
Dec 06Does China Resources Pharmaceutical Group (HKG:3320) Have A Healthy Balance Sheet?
Sep 07Does This Valuation Of China Resources Pharmaceutical Group Limited (HKG:3320) Imply Investors Are Overpaying?
Aug 02With EPS Growth And More, China Resources Pharmaceutical Group (HKG:3320) Makes An Interesting Case
May 26These 4 Measures Indicate That China Resources Pharmaceutical Group (HKG:3320) Is Using Debt Reasonably Well
May 05China Resources Pharmaceutical Group's (HKG:3320) Shareholders Will Receive A Bigger Dividend Than Last Year
Apr 04Is There An Opportunity With China Resources Pharmaceutical Group Limited's (HKG:3320) 24% Undervaluation?
Jan 24Is China Resources Pharmaceutical Group (HKG:3320) Using Too Much Debt?
Dec 15China Resources Pharmaceutical Group Limited's (HKG:3320) Intrinsic Value Is Potentially 97% Above Its Share Price
Oct 18China Resources Pharmaceutical Group (HKG:3320) Takes On Some Risk With Its Use Of Debt
Aug 27China Resources Pharmaceutical Group (HKG:3320) Has Announced That It Will Be Increasing Its Dividend To HK$0.15
May 29China Resources Pharmaceutical Group (HKG:3320) Is Increasing Its Dividend To HK$0.15
May 02China Resources Pharmaceutical Group's (HKG:3320) Upcoming Dividend Will Be Larger Than Last Year's
Apr 07China Resources Pharmaceutical Group (HKG:3320) Has A Somewhat Strained Balance Sheet
Mar 31Are Investors Undervaluing China Resources Pharmaceutical Group Limited (HKG:3320) By 23%?
Feb 21Here's Why China Resources Pharmaceutical Group (HKG:3320) Can Manage Its Debt Responsibly
Dec 07China Resources Pharmaceutical Group Limited (HKG:3320) Shares Could Be 32% Below Their Intrinsic Value Estimate
Nov 10These 4 Measures Indicate That China Resources Pharmaceutical Group (HKG:3320) Is Using Debt Reasonably Well
Aug 29Is China Resources Pharmaceutical Group Limited (HKG:3320) Trading At A 21% Discount?
Aug 03Is China Resources Pharmaceutical Group Limited (HKG:3320) A Good Fit For Your Dividend Portfolio?
May 03Is China Resources Pharmaceutical Group (HKG:3320) A Risky Investment?
Apr 12Is China Resources Pharmaceutical Group Limited's (HKG:3320) Recent Stock Performance Influenced By Its Fundamentals In Any Way?
Mar 17An Intrinsic Calculation For China Resources Pharmaceutical Group Limited (HKG:3320) Suggests It's 24% Undervalued
Feb 14If You Had Bought China Resources Pharmaceutical Group's (HKG:3320) Shares Three Years Ago You Would Be Down 63%
Jan 17
We Think China Resources Pharmaceutical Group (HKG:3320) Is Taking Some Risk With Its Debt
Nov 29Financial Position Analysis
Short Term Liabilities: 3320's short term assets (CN¥178.6B) exceed its short term liabilities (CN¥134.2B).
Long Term Liabilities: 3320's short term assets (CN¥178.6B) exceed its long term liabilities (CN¥19.6B).
Debt to Equity History and Analysis
Debt Level: 3320's net debt to equity ratio (38.9%) is considered satisfactory.
Reducing Debt: 3320's debt to equity ratio has reduced from 89.2% to 65.5% over the past 5 years.
Debt Coverage: 3320's debt is not well covered by operating cash flow (17.6%).
Interest Coverage: 3320's interest payments on its debt are well covered by EBIT (6.2x coverage).